针对多药耐药性和广泛耐药性Acinetobacter baumannii感染的当前治疗方法
Petros Rafailidis1, Periklis Panagopoulos1, Christos Koutserimpas2
1Second University Department of Internal Medicine, University General Hospital of Alexandroupolis, 681 00 Alexandroupolis, Greece.
治疗Acinetobacter baumannii感染是很困难的,因为它的耐药性. 新的抗生素,如 cefiderocol 提供对抗多药耐药 (MDR) 和广泛耐药 (XDR) 菌株的希望.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在全球范围内,Acinetobacter baumannii感染是一个重大的健康挑战.
- 该细菌表现出广泛的抗药机制,使治疗复杂化.
- 在COVID-19大流行期间观察到A. baumannii的超级感染.
研究的目的:
- 审查针对多药耐药 (MDR) 和广泛耐药 (XDR) Acinetobacter baumannii感染的治疗进展.
- 总结过去十年关于治疗策略的现有信息.
- 突出对抗A. baumannii感染的挑战和进展.
主要方法:
- 在过去十年中发表的研究的文献综述.
- 对A. baumannii.抗生素耐药性概况的分析.
- 评估各种抗微生物药物的疗效.
主要成果:
- 新的β-乳酸/β-乳酸酶抑制剂对A. baumannii. 的有效性有限.
- 已经确定的药物如硫巴克坦,聚米辛,tigecycline和aminoglycosides对于MDR/XDR感染至关重要.
- 塞菲德罗科尔代表了治疗武器库的宝贵补充.
结论:
- 治疗A. baumannii感染需要根据耐药性模式仔细选择抗生素.
- 尽管面临挑战,但治疗方面的进步,包括诸如 cefiderocol 这样的新药,正在改善治疗选择.
- 持续的研究和开发对于克服A. baumannii的抗生素耐药性至关重要.
更多相关视频
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
09:29In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Published on: April 28, 2017
相关概念视频
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Antibiotic Selection
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
